A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients

This is a clinical study aiming to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory Acute Myeloid Leukemia patients.

Trial Details

NCT ID
NCT07303660
Phase
PHASE1
Sponsor
Lomond Therapeutics Holdings, Inc.
Status
RECRUITING
Cancer Type
Acute Myeloid (AML) Leukemia
Interventions
  • ZE50-0134
  • Azacitidine Days 1-7
  • ZE 50-0134
Locations (sample)
  • Moscow, Moscow, Russia|55.75204,37.61781
  • Krasnogorsk, Moscow Oblast, Russia|55.81904,37.32984
  • Velikiy Novgorod, Novgorod Oblast, Russia|58.52131,31.27104
  • Saint Petersburg, Sankt-Peterburg, Russia|59.93863,30.31413
  • Saint Petersburg, Sankt-Peterburg, Russia|59.93863,30.31413

Key Eligibility Criteria

  • 1\. Patients must be able to understand and provide written informed consent. 2. AML patients: For the dose escalation and expansion, patients aged…
  • 3\. At the time of Lonitoclax initiation, white blood count (WBC) needs to be \< 25 × 109/L: Hydroxyurea can be used to achieve that level.
  • 4\. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2. 5. Adequate organ function as defined by the following:
  • Aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN), alanine aminotransferase (ALT) ≤ 2.5 x ULN. AST and/or ALT may be up to 5 x U…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Myeloid (AML) Leukemia Trials on Trialify →